Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.

Blood
Jane MountK A High

Abstract

Hemophilia B is an X-linked coagulopathy caused by absence of functional coagulation factor IX (FIX). Using adeno-associated virus (AAV)-mediated, liver-directed gene therapy, we achieved long-term (> 17 months) substantial correction of canine hemophilia B in 3 of 4 animals, including 2 dogs with an FIX null mutation. This was accomplished with a comparatively low dose of 1 x 10(12) vector genomes/kg. Canine FIX (cFIX) levels rose to 5% to 12% of normal, high enough to result in nearly complete phenotypic correction of the disease. Activated clotting times and whole blood clotting times were normalized, activated partial thromboplastin times were substantially reduced, and anti-cFIX was not detected. The fourth animal, also a null mutation dog, showed transient expression (4 weeks), but subsequently developed neutralizing anti-cFIX (inhibitor). Previous work in the canine null mutation model has invariably resulted in inhibitor formation following treatment by either gene or protein replacement therapies. This study demonstrates that hepatic AAV gene transfer can result in sustained therapeutic expression in a large animal model characterized by increased risk of a neutralizing anti-FIX response.

References

Jul 1, 1992·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·R P VemuruS Gupta
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J P EvansK A High
Mar 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·M A KayA R Thompson
Jan 5, 1994·JAMA : the Journal of the American Medical Association·J N Lozier, K M Brinkhous
Jun 1, 1996·Baillière's Clinical Haematology·F Giannelli, P M Green
Jan 1, 1995·Advances in Experimental Medicine and Biology·K A High
May 20, 1998·Nature Genetics·C H MiaoM A Kay
Sep 25, 1999·Human Gene Therapy·R J Kaufman
May 12, 2000·Immunological Reviews·P A Knolle, G Gerken
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·L WangI M Verma
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·P A FieldsK A High
Feb 7, 2001·Circulation Research·K A High
May 1, 2001·British Journal of Haematology·R LjungE Sjörin
Sep 8, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·R W HerzogC D Lothrop
Sep 8, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·P A FieldsK A High

❮ Previous
Next ❯

Citations

Dec 5, 2002·International Journal of Hematology·Katherine A High
Jul 27, 2007·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Kate L TsaiKeith E Murphy
Apr 14, 2006·Human Genetics·Kenneth H Warrington, Roland W Herzog
Nov 19, 2004·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Stefan Worgall
Jan 28, 2003·Trends in Immunology·Ghislain OpdenakkerBernd Arnold
Oct 23, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sachiko OhshimaShin'ichi Takeda
Aug 27, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Herena EixarchJordi Barquinero
Apr 16, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hua LiHildegund C J Ertl
Apr 23, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sharon C CunninghamIan E Alexander
Aug 12, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Paul E MonahanR Jude Samulski
Aug 26, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gregory D HurlbutRonald K Scheule
Nov 18, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Denise E SabatinoHaig H Kazazian
Dec 2, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lauren E Mays, James M Wilson
Dec 16, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hua LiHildegund C J Ertl
May 9, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Federico MingozziKatherine A High
Mar 21, 2007·Nature Medicine·Federico MingozziKatherine A High
Dec 8, 2005·European Journal of Human Genetics : EJHG·Margret Casal, Mark Haskins
Nov 30, 2007·Gene Therapy·A Zaldumbide, R C Hoeben
Jan 25, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hua LiHildegund Cj Ertl
Oct 24, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Samuel L MurphyKatherine High
Jul 23, 2003·Journal of Thrombosis and Haemostasis : JTH·G C White
Oct 13, 2005·Human Gene Therapy·Alessandra Biffi, Luigi Naldini
May 27, 2005·Human Gene Therapy·Barrie J Carter
Mar 25, 2009·Human Gene Therapy·Mario CooperRoland W Herzog
Jan 6, 2011·Human Gene Therapy·Peter BellJames M Wilson
Jun 8, 2012·Human Gene Therapy·Marinee K ChuahThierry VandenDriessche
Sep 2, 2005·The Journal of Heredity·J Aguirre-Hernández, D R Sargan
Jun 1, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·Changyu ZhengBruce J Baum
Aug 13, 2002·Current Opinion in Hematology·Paul E Monahan, Gilbert C White
Oct 24, 2002·Current Opinion in Hematology·Catherine S Manno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.